
Russ Belden
Russ is a biotech commercialization leader with over 35 years of senior leadership experience in strategic marketing, sales management, operations, sales training, and product development. Starting as employee 15 in Genentech’s SSF Commercial organization, he spent 16 years there launching products/indications across multiple therapeutic areas, including a pivotal role in launching their BioOncology franchise and left as the Director of Hematology Sales.
As Founder/President & CEO of Bridge – Your iCCO Company, he has worked with over 100 emerging biotech companies over the past 17 years. Russ provides critical commercial leadership to Phase III emerging biotech companies as an interim Chief Commercial Officer (iCCO). As the company’s iCCO he leads all the commercialization imperatives, establishes the “blueprint” for the Commercial / Medical Affairs organization and develops a 3-year expense budget including all commercialization costs enabling the company to successfully position its lead product(s) for commercial launch while absorbing the risk of a potentially negative Phase 3 readout. Russ is currently the iCCO at five Phase 3 companies.
Bridge also develops rigorous commercial assessments for pre-clinical to Phase 2 companies whose outputs are used for portfolio decisions and to support investor/Business Development initiatives. That work also defines the early differentiation of the asset.
Russ is the co-developer and leader of the Biotech Primer two-day course, “BioPharma” Revenue Forecasting that Drives Decision Making and Investments. He earned a Bachelor of Science degree in Pharmacy from the University of New York at Buffalo.
Speaking In
-
15-Jun-2025